Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema

Current Opinion in Investigational Drugs

Volumn 11, Issue 11, 2010, Pages 1286-1294

  Antoniu, Sabina A ^a  

^a GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

[No Author keywords available]

Indexed keywords

AIR 645; ALLERGEN; AMG 317; ANTIASTHMATIC AGENT; BAY 16 9996; CINTREDEKIN BESUDOTOX; CORTICOSTEROID; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 13; INTERLEUKIN 4; LEBRIKIZUMAB; MK 6105; PITRAKINRA; PLACEBO; QAX 576; TRALOKINUMAB; UNCLASSIFIED DRUG;

ANTIBODY DETECTION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASCARIS SUUM; ASTHMA; ATOPIC DERMATITIS; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ASSESSMENT; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG SCREENING; DRUG SYNTHESIS; DRUG TOLERABILITY; DRY POWDER; DYSPNEA; ENDOTHELIUM CELL; ESCHERICHIA COLI; FOLLOW UP; FORCED EXPIRATORY VOLUME; HUMAN; IC 50; IN VIVO STUDY; INJECTION SITE REACTION; LYMPHOCYTE; NEBULIZER; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SITE DIRECTED MUTAGENESIS; STRUCTURE ACTIVITY RELATION; THORAX PAIN; TREATMENT DURATION; WHEEZING;

EID: 78650405860     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. 317452 Company brochure. Bayer AG COMPANY BROCHURE 1998 March 05
2. 340531 Allergen-induced airway inflammation and bronchial responsiveness in wild-type and interleukin-4-deficient mice. Brusselle G, Kips J, Joos G, Bluethmann H, Pauwels R AM J RESPIR CELL MOL BIOL 1995 12 3 254-259
3. 402555 Preclinical evaluation of Bay 16-9996 a dual IL-4/IL13 receptor antagonist. Gundel R, Morton M, Bowden A, Fitch N, Shanafelt MC, Shanafelt A, Wetzel G, Moy J, Gibbons J, Terrell T EUR RESPIR J SUPPL 2000 16 Suppl 31 Abs P3964
4. 412104 Preclinical evaluation of BAY 16-9996 a dual IL-4/IL-13 receptor antagonist. Fitch N, Morton M, Bowden A, Shanafelt A, Wetzel G, Moy J J ALLERGY CLIN IMMUNOL 2001 107 2 Abs 209
5. 479772 A 13-week toxicity study of BAY 16-9996 (an IL-4 receptor antagonist) in male and female rhesus monkeys with a 4-week recovery period. Ji C, Horner M, Newgren J, Cheung E, Burmeister BE, Boes M, Neyer L, Rousselle S, Reynolds T TOXICOL SCI 2002 66 1 Abs 1588
6. 555703 Apax Partners forms Aerovance Inc through spin out of Bayer Biotechnology Respiratory Projects. Apax Partners PRESS RELEASE 2004 August 23
7. 637440 Pipeline. Aerovance Inc COMPANY WORLD WIDE WEB SITE 2005 November 25
8. 743031 IL-13 receptor α2: A regulator of IL-13 and IL-14 signal transduction in primary human fibroblasts. Andrews AL, Nasir T, Bucchieri F, Holloway JW, Holgate ST, Davies DE J ALLERGY CLIN IMMUNOL 2006 118 4 858-865
9. 803582 NeoPharm Inc signs exclusive license agreement for the use of cintredekin besudotox (IL13-PE38QQR) for the treatment of pulmonary fibrosis and asthma. NeoPharm Inc PRESS RELEASE 2007 June 11
10. 835800 NCT00535431: Effects of AER 001 administered by nebulization on antigen challenge in atopic asthmatics. Aerovance Inc CLINICALTRIALS.GOV 2007
11. 845969 Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: Results of two phase 2a studies. Wenzel S, Wilbraham D, Fuller R, Getz E, Lonphre M LANCET 2007 370 9596 1422-1431
12. 871931 CSL: Profile and pipeline. CSL Ltd COMPANY WORLD WIDE WEB SITE 2008 January 29
13. 943270 Inhibition of Il-4RA: A promising therapeutic strategy for asthma. Tocker J, Horner M, Vincent M, Banfield C, Lin SL INFLAMM RES ASSOC INT CONF 2008 15 September 24 Abs SA22
14. 1032087 The effects of an IL-4 receptor antagonist (BAY 16-9996) on antigen-induced cutaneous wheal and flare reactions in the primate. Morton M, Harris P, Xu J, Gorina S, Roczniak S, Fitch N, Gundel R AM J RESPIR CRIT CARE MED 1999 159 3 A660
15. 1032088 The IL-4 receptor antagonist (BAY 16-9996) reverses airway hyperresponsiveness in a primate model of asthma. Harris P, Lindell D, Fitch N, Gundel R AM J RESPIR CRIT CARE MED 1999 159 3 A230
16. 1042635 Human pharmacokinetics/pharmacodynamics of an interleukin-4 and interleukin-13 dual antagonist in asthma. Getz EB, Fisher DM, Fuller R J CLIN PHARMACOL 2009 49 9 1025-1036
17. 1073691 Cytokine antagonists for the treatment of asthma progress to date. Antoniu SA BIODRUGS 2009 23 4 241-251
18. 1086746 MEDI-528, an anti-IL-9 humanized antibody for the treatment of asthma. Antoniu SA CURR OPIN MOL THER 2010 12 2 233-239
19. 1094340 American Academy of Allergy, Asthma and Immunology (AAAAI) - 2010 Annual Meeting. Bielory L IDRUGS 2010 13 5 304-307
20. 1099867 A murine IL-4 receptor antagonist that inhibits IL-4- and IL-13-induced responses prevents antigen-induced airway eosinophilia and airway hyperresponsiveness. Tomkinson A, Duez C, Cieslewicz G, Pratt JC, Joetham A, Shanafelt MC, Gundel R, Gelfand EW J IMMUNOL 2001 166 9 5792-5800
21. 1099868 Inhibition of IL-4 and IL-13 with an IL-4 mutein (Aeroderm) protects against flares in atopic eczema. Groves RW, Wilbraham D, Fuller R, Longphre M J INVEST DERMATOL 2007 127 Abs 320
22. 1099869 Inhaled vs subcutaneous effects of a dual IL-4/IL-13 antagonist in a monkey model of asthma. Tomkinson A, Tepper J, Morton M, Bowden A, Stevens L, Harris P, Lindell D, Fitch N, Gundel R, Getz EB ALLERGY 2010 65 1 69-77
23. 1125382 Inhaled IL-4/IL-13 antagonist decreases response to antigen challenge in atopic asthmatic subjects. Wilbraham D, Getz EB, Longphre M, Wenzel S, Fuller R EUR RESPIR J 2007 30 Suppl 51 Abs 2959
24. 1125383 AER 001 effects on antigen challenge in atopic asthmatic subjects. Wilbraham D, Fuller R ANNU CONGR EUR RESP SOC 2006 16 September 2-6 Abs 746
25. 1125384 Therapeutic effects of inhaled AER 001, an IL-4/IL-13 antagonist, on allergen-induced airway hyperresponsiveness (AHR) and airway inflammation. Tomkinson A, Stevens L, Morton M, Chen J, Wong T, Burmeister GE, Bowden A, Tepper J PROC AM THORAC SOC 2006 3 Abs 521
26. 1125385 Mechanism of action of an IL-4 receptor antagonist (BAY 16-9996) in the primate model of asthma. Shanafelt MC, Harris P, Neyer L, Moy J, Barrientos J, Gundel R AM J RESPIR CRIT CARE MED 2000 161 3, Part 2 A201
27. 1125386 Pharmacokinetics of subcutaneous and inhaled IL-4/IL-13 antagonist in humans. Getz EB, Fisher D, Tomkinson A, Longphre M, Fuller R AM J RESPIR CRIT CARE MED 2008 177 Abs 70
28. 1127023 Allergen-induced early and late asthmatic responses are not affected by inhibition of endogenous nitric oxide. Taylor DA, McGrath JL, O'Connor BJ, Barnes PJ AM J RESPIR CRIT CARE MED 1998 158 1 99-106
29. 1127026 Role of interleukin-4 and vascular cell adhesion molecule-1 in selective eosinophil migration into the airways in allergic asthma. Fukuda T, Fukushima Y, Numao T, Ando N, Arima M, Nakajima H, Sagara H, Adachi T, Motojima S, Makino S AM J RESPIR CELL MOL BIOL 1996 14 1 84-94
30. 1127028 IL-13 as a therapeutic target for respiratory disease. Kasaian MT, Miller DK BIOCHEM PHARMACOL 2008 76 2 147-155
31. 1127039 Interleukin-4: Its role in the pathogenesis of asthma, and targeting it for asthma treatment with interleukin-4 receptor antagonists. Steinke JW, Borish L RESPIR RES 2001 2 2 66-70
32. 1127112 The gene encoding interleukin-13: A susceptibility locus for asthma and related traits. Wills-Karp M RESPIR RES 2000 1 1 19-23
33. 1127113 Bronchoalveolar lavage fluid concentrations of transforming growth factor (TGF)-β1, TGF-β2, interleukin (IL)-4 and IL-13 after segmental allergen challenge and their effects on α-smooth muscle actin and collagen III synthesis by primary human lung fibroblasts. Batra V, Musani AI, Hastie AT, Khurana S, Carpenter KA, Zangrilli JG, Peters SP CLIN EXP ALLERGY 2004 34 3 437-444
34. 1127277 Interleukin-13 in asthma pathogenesis. Wills-Karp M CURR ALLERGY ASTHMA REP 2004 4 2 123-131 (Pubitemid 38906753)
35. 1127324 IL-13 effector functions. Wynn TA ANNU REV IMMUNOL 2003 21 425-456
36. 1127350 Attenuation of allergic airway inflammation in IL-4 deficient mice. Brusselle GG, Kips JC, Tavernier JH, van der Heyden JG, Cuvelier CA, Pauwels RA, Bluethmann H CLIN EXP ALLERGY 1994 24 1 73-80
37. 1127354 Allergen-induced cytokine production in atopic disease and its relationship to disease severity. Leonard C, Tormey V, Burke C, Poulter LW AM J RESPIR CELL MOL BIOL 1997 17 3 368-375
38. 1127358 Inhibition of allergic airways inflammation and airway hyperresponsiveness in mice by dexamethasone: Role of eosinophils, IL-5, eotaxin, and IL-13. Eum SY, Maghni K, Hamid Q, Eidelman DH, Campbell H, Isogai S, Martin JG J ALLERGY CLIN IMMUNOL 2003 111 5 1049-1061
39. 1127362 Increased interleukin-13 mRNA expression in bronchoalveolar lavage cells of atopic patients with mild asthma after repeated low-dose allergen provocations. Prieto J, Lensmar C, Roquet A, Van der Ploeg I, Gigliotti D, Eklund A, Grunewald J RESPIR MED 2000 94 8 806-814
40. 1127367 The interleukin-4/interleukin-13 receptor of human synovial fibroblasts: Overexpression of the nonsignaling interleukin-13 receptor α2. Feng N, Lugli SM, Schnyder B, Gauchat JFM, Graber P, Schlagenhauf E, Schnarr B, Wiederkehr-Adam M, Duschl A, Heim MH, Lutz RA et al LAB INVEST 1998 78 5 591-602
41. 1127368 Investigational therapeutics targeting the IL-4/IL-13/ STAT-6 pathway for the treatment of asthma. Oh C, Geba GP, Molfino N EUR RESPIR REV 2010 19 115 46-54
42. 1127400 T-helper type 2-driven inflammation defines major subphenotypes of asthma. Woodruff PG, Modrek B, Choy DF, Jia GQ, Abbas AR, Ellwanger A, Arron JR, Koth LL, Fahy JV AM J RESPIR CRIT CARE MED 2009 180 5 388-395
43. 1128211 GINA Report: Global strategy for asthma management and prevention. GINA Executive Committee, GINA Science Committee WEB SITE 2009 December 31
44. 1128259 Asthma. World Health Organization WHO: WORLD HEALTH REP 2008 December 31
45. 1128310 Specific antagonism of type I IL-4 receptor with a mutated form of murine IL-4. Schnare M, Blum H, Juttner S, Rollinghoff M, Gessner A J IMMUNOL 1998 161 7 3484-3492
46. 1128324 Design of human interleukin-4 antagonists inhibiting interleukin-4-dependent and interleukin-13-dependent responses in T-cells and B-cells with high-efficiency. Tony HP, Shen BJ, Reusch P, Sebald W EUR J BIOCHEM 1994 225 2 659-665
47. 1128326 An antagonistic mutant of interleukin-4 fails to recruit γ-c into the receptor complex - Characterization by specific cross-linking. DUSCHL A EUR J BIOCHEM 1995 228 2 305-310
48. 1128398 AER 003, a PEGylated IL-4/IL-13 antagonist, significantly reduces allergen-induced airway hyperresponsiveness (AHR). Tomkinson A ANN ALLERGY ASTHMA IMMUNOL 2010 February 27 Abs 214
49. 1128495 Pharmacokinetics and local tolerance of an IL-4/IL-13 antagonist inhalation powder in humans. Getz EB, Wilbraham D, Lalor C, Longphre M, Fuller R ANNU CONGR EUR RESP SOC 2008 October 07 Abs 3191
50. 1128735 Aerovance company pipeline: Aerovant and Aeroderm. Aerovance Inc COMPANY WORLD WIDE WEB SITE 2009 December 30
51. 1131151 A functional IL-13 receptor is expressed on polarized murine CD4+ Th17 cells and IL-13 signaling attenuates Th17 cytokine production. Newcomb DC, Zhou WS, Moore ML, Goleniewska K, Hershey GKK, Kolls JK, Peebles RS J IMMUNOL 2009 182 9 5317-5321
52. 1132868 Esp@cenet: Legal status of EP-00613499. Esp@cenet WEB SITE 1998 December 30
53. 1133635 Inhaled pitrakinra, an IL-4/IL-13 antagonist, reduced exacerbations in patients with eosinophilic asthma. Wenzel SE, Ind PW, Otulana BA, Bleecker ER, Kuna P, Yen YP ANNU CONGR EUR RESP SOC 2010 20 September 18-22 Abs P3980